Join the club for FREE to access the whole archive and other member benefits.

Matt Whiteman

Inventor, Co-founder and CSO at MitoRx Therapeutics and professor at Mahidol University in Thailand

Professor of Experimental Therapeutics, University of Exeter, University of Otago, NZ  (2006) and University of Mahidol, Thailand (2018, 2022-). Key to elucidating the role of H₂S in vivo and invented the first mitochondrial-targeted sulfide-delivery molecules. Grant awards totalling £6m for mitochondrial H₂S rescue of diseases. 20 years experience of redox biochemistry and pharmacology in UK and Singapore. 180+ publications, H-index = 78.

Visit website: https://www.mitorxtherapeutics.com/#Our-team/#matt

See also: Company MitoRx Therapeutics - Pre-clinical stage rare disease biotech company aiming to develop treatments for degenerative diseases

Details last updated 27-Aug-2022

Matt Whiteman is also referenced in the following:

MitoRx Therapeutics

Pre-clinical stage rare disease biotech company aiming to develop treatments for degenerative diseases

Matt Whiteman News

Penetrable sunscreen agents could reverse skin damage and ageing

SciTechDaily - 12-Aug-2021

Two novel compounds fuel mitochondria to maintain energy balance and lower UV damage in the skin

Read more...